

**Amendments to the Claims**

What is claimed is:

1. (original) A method of treating gastroparesis in a patient suffering therefrom which comprises administering to said patient an effective amount of a GLP-1 compound.
2. (original) The method of claim 1 wherein the patient also suffers from diabetes.
3. (original) The method of Claim 2 wherein the patient suffers from type 2-diabetes.
4. (original) The method of any one of Claims 1 to 3 wherein the GLP-1 compound is selected from the group consisting of GLP-1(7-36)amide, GLP-1(7-37), GLP-1 analogs, and GLP-1 derivatives.
5. (original) The method of any one of Claims 1 to 3 wherein the GLP-1 compound is selected from the group consisting of: Exendin-4, Exendin-4 analogs, and Exendin-4 derivatives.
6. (original) The method of any one of Claims 1 to 3 wherein the GLP-1 compound is an agonist of the GLP-1 receptor.
7. (original) The method of any one of Claims 1 to 3 wherein the GLP-1 compound is a DPP-IV resistant analog.
8. (original) The method of Claim 7 wherein the GLP-1 compound is a GLP-1 analog or derivative having glutamic acid at position 22.
9. (original) The method of Claim 7 wherein the GLP-1 compound is a GLP-1 analog having valine or glycine at position 8.
10. (original) The method of any one of Claims 1 to 3 wherein the GLP-1 compound is a GLP-1 derivative.

11. (original) The method of Claim 10 wherein the GLP-1 derivative is an acylated GLP-1 analog.
12. (original) The method of Claim 11 wherein the GLP-1 derivative is Arg<sup>34</sup>Lys<sup>26</sup>-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37).
13. (original) The method of any one of Claims 1 to 12 wherein the GLP-1 compound is administered by subcutaneous injection.
14. (original) The method of any one of Claims 1 through 12 wherein the GLP-1 compound is administered orally.
15. (original) The method of any one of Claims 1 through 12 wherein the GLP-1 compound is administered by buccal administration.
16. (cancelled)
17. (cancelled)